Clinical Scorecard: Exploring Preclinical Subtypes of Type 2 Diabetes Mellitus: Insights into the Links Between Diabetes, Depression, and Cognitive Decline

At a Glance

Key Highlights

• Two preclinical T2DM subtypes identified: leptin-resistant subtype linked to psychiatric disorders and slower diabetes progression, and glycaemic-focused subtype linked to neurodegenerative diseases and stronger genetic diabetes associations.
• Metabolic disturbances influencing brain health begin years before formal T2DM diagnosis, affecting cognition, brain structure, and psychiatric/neurological comorbidities.
• Distinct metabolic pathways suggest subtype-specific intervention strategies targeting inflammation and leptin signalling for psychiatric risk, and insulin sensitization for cognitive decline prevention.

Guideline-Based Recommendations

Diagnosis

• Consider metabolic subtyping in preclinical T2DM using biomarkers such as leptin levels, leptin receptor expression, fasting glucose, and HbA1c to identify risk profiles.
• Utilize data-driven algorithms (e.g., SuStaIn) for early detection of T2DM subtypes to inform prognosis.

Management

• Implement subtype-specific interventions: anti-inflammatory and leptin-targeted therapies for leptin-resistant subtype; insulin-sensitizing and neuroprotective treatments for glycaemic-focused subtype.
• Maintain glycaemic control as central to diabetes management, potentially employing continuous glucose monitoring (CGM) to prevent cognitive decline.
• Explore early anti-diabetic treatments at preclinical stages to preserve mental health and reduce neurodegeneration risk.

Monitoring & Follow-up

• Monitor cognitive function and psychiatric symptoms longitudinally in individuals with preclinical T2DM.
• Assess brain structural changes and neurodegenerative markers in high-risk subtypes.
• Evaluate treatment effects on metabolic profiles and brain health outcomes.

Risks

• Increased risk of depression, anxiety, bipolar disorder, and sleep disorders in leptin-resistant subtype.
• Elevated risk of Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions in glycaemic-focused subtype.
• Potential progression to overt T2DM with associated complications if metabolic disturbances remain unaddressed.

Patient & Prescribing Data

Individuals with preclinical or early-stage T2DM exhibiting distinct metabolic profiles

Metformin shows inconsistent neurocognitive benefits; GLP-1 receptor agonists like semaglutide demonstrate promise in reducing dementia incidence and are under investigation for slowing Alzheimer’s progression.

Clinical Best Practices

• Adopt early metabolic subtyping to tailor interventions and improve brain health outcomes in T2DM.
• Focus on integrated management addressing both metabolic and neuropsychiatric aspects of diabetes.
• Encourage longitudinal monitoring of cognitive and psychiatric status alongside metabolic parameters.
• Promote public health strategies to improve metabolic control and treatment adherence in high-risk populations.

References

• Yi et al., Machine learning reveals connections between preclinical type 2 diabetes subtypes and brain health
• Evidence on depression prevalence and bidirectional relationship with T2DM
• Diabetes and depression as modifiable risk factors for dementia
• Subtype and Stage Inference (SuStaIn) algorithm for disease progression
• GLP-1 receptor agonists and dementia incidence
• Nationwide digital health intervention for diabetes management in China